RESEARCH OPPORTUNITIES
Generalizability Network Research Study @aaveritt ’s presentation from the July 10th community call: https://drive.google.com/file/d/1acWhR5FCsTMWL7hxmYCgVlUt6r1bBFm1/view?usp=sharing @aaveritt know by replying to her forum post:Generalizability, Applicability, and Replicability of RCTs: A Study
OHDSI MEETINGS THIS WEEK
OHDSI Community Call - Tuesday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=811649.9868221112121212
Population-Level Estimation (Eastern hemisphere) Workgroup Call - Wednesday at 3pm Hong Kong timehttps://meetings.webex.com/collabs/meetings/join?uuid=M6WE9AOKFETH2VEFPVCZWWBIT0-D1JL
Architecture Working Group - Thursday at 10am EThttps://jjconferencing.webex.com/mw3100/mywebex/default.do?service=1&siteurl=jjconferencing&nomenu=true&main_url=%2Fmc3100%2Fe.do%3Fsiteurl%3Djjconferencing%26AT%3DMI%26EventID%3D610982452%26UID%3D501476547%26Host%3DQUhTSwAAAAQu4P1o9qm71JJ1Zj4-uvZbjQttsCinu71JCRxBAHAXnzjjRAiTspTzU9ojLmjMF4CcTBWw4zn1dqYPTWu5vJ9_0%26FrameSet%3D2%26MTID%3Dm3e1ceeca56f1e94c9fcf1ae98c10e02e
Cerner to OMOP Workgroup meeting - Thursday from 10:30am to 11:30am PT (1:30-2:30pm ET)https://global.gotomeeting.com/join/672436613
GIS Working Group Meeting - Next Monday (August 27th) at 10am ET
Simple, modern video meetings for the global workforce. Join from anywhere, including your desktop, browser, mobile device, or video room device.
ANNOUNCEMENTS
2018 OHDSI Titan Awards - SUBMIT NOMINATIONS NOW! Please submit your nominations here: https://docs.google.com/forms/d/e/1FAIpQLScO61Fsi73St071J5bt0hH2Guku57fay46404-V0r6gNvrwXg/viewform Deadline to submit nominations is 5pm ET on September 17th
2018 Collaborator Showcase - Call for participation CLOSED https://www.ohdsi.org/collaborator-showcase/
2018 OHDSI Symposium - REGISTER NOW https://www.ohdsi.org/symposium-registration-2/1
2018 OHDSI Symposium - TUTORIAL REGISTRATION OPEN https://www.ohdsi.org/tutorial-workshops/ https://www.ohdsi.org/tutorial-registration-2/
Intro tutorials are being offered free of cost, however registration does not guarantee a seat in the tutorial. When you register, you will be placed on the tutorial wait-list. The final participant list will be determined by the tutorial faculty.
Advanced tutorials also offer the free wait-list registration. In addition, we are also offering a limited number of paid tickets ($318.17) which will guarantee your seat in the tutorial.
Call for Community Feedback Guidelines for starting an OHDSI chapter Guidelines for starting an OHDSI working group
The pendulum of the mind alternates between sense and nonsense, not between right and wrong.
COMMUNITY PUBLICATIONS
Database Studies of Treatment-Resistant Depression Should Take Account of Adequate Dosing.https://europepmc.org/abstract/med/30084549
A hackathon promoting Taiwanese health-IoT innovation.
U Iqbal, A Dagan, S Syed-Abdul, LA Celi, S Malwade, MH Hsu and YJ Li,
Computer methods and programs in biomedicine , Sep 2018
Construction of an Electrocardiogram Database Including 12 Lead Waveforms.
D Chung, J Choi, JH Jang, TY Kim, J Byun, H Park, HS Lim, RW Park and D Yoon,
Healthcare informatics research , Jul 2018
Electrocardiogram (ECG) data are important for the study of cardiovascular disease and adverse drug reactions. Although the development of analytical techniques such as machine learning has improved our ability to extract useful information from ECGs, there is a lack of easily available ECG data for research purposes. We previously published an article on a database of ECG parameters and related clinical data (ECG-ViEW), which we have now updated with additional 12-lead waveform information.All ECGs stored in portable document format (PDF) were collected from a tertiary teaching hospital in Korea over a 23-year study period. We developed software which can extract all ECG parameters and waveform information from the ECG reports in PDF format and stored it in a database (meta data) and a text file (raw waveform).Our database includes all parameters (ventricular rate, PR interval, QRS duration, QT/QTc interval, P-R-T axes, and interpretations) and 12-lead waveforms (for leads I, II, III, aVR, aVL, aVF, V1, V2, V3, V4, V5, and V6) from 1,039,550 ECGs (from 447,445 patients). Demographics, drug exposure data, diagnosis history, and laboratory test results (serum calcium, magnesium, and potassium levels) were also extracted from electronic medical records and linked to the ECG information.Electrocardiogram information that includes 12 lead waveforms was extracted and transformed into a form that can be analyzed. The description and programming codes in this case report could be a reference for other researchers to build ECG databases using their own local ECG repository.
MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study, and docking calculations.
GL Delogu, F Pintus, L Mayán, MJ Matos, S Vilar, J Munín, JA Fontenla, G Hripcsak, F Borges and D Viña,
MedChemComm , Sep 2017 01
Monoamine oxidase (MAO) is an enzyme responsible for metabolism of monoamine neurotransmitters which play an important role in brain development and function. This enzyme exists in two isoforms, and it has been demonstrated that MAO-B activity, but not MAO-A activity, increases with aging. MAO inhibitors show clinical value because besides the monoamine level regulation they reduce the formation of by-products of the MAO catalytic cycle, which are toxic to the brain. A series of 2-phenylbenzofuran derivatives was designed, synthesized and evaluated against hMAO-A and hMAO-B enzymes. A bromine substituent was introduced in the 2-phenyl ring, whereas position 5 or 7 of the benzofuran moiety was substituted with a methyl group. Most of the tested compounds inhibited preferentially MAO-B in a reversible manner, with IC50 values in the low micro or nanomolar range. The 2-(2'-bromophenyl)-5-methylbenzofuran (5) was the most active compound identified (IC50 = 0.20 μM). In addition, none of the studied compounds showed cytotoxic activity against the human neuroblastoma cell line SH-SY5Y. Molecular docking simulations were used to explain the observed hMAO-B structure-activity relationship for this type of compounds.
Post-publication peer review and evidence appraisals in primary care.
AN Sahin, A Goldstein and C Weng,
Lancet (London, England) , 2018 08 04
Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges.
EC Lai, P Ryan, Y Zhang, M Schuemie, NC Hardy, Y Kamijima, S Kimura, K Kubota, KK Man, SY Cho, RW Park, P Stang, CC Su, IC Wong, YY Kao and S Setoguchi,
Clinical epidemiology , 2018
The goal of the Asian Pharmacoepidemiology Network is to study the effectiveness and safety of medications commonly used in Asia using databases from individual Asian countries. An efficient infrastructure to support multinational pharmacoepidemiologic studies is critical to this effort.We converted data from the Japan Medical Data Center database, Taiwan's National Health Insurance Research Database, Hong Kong's Clinical Data Analysis and Reporting System, South Korea's Ajou University School of Medicine database, and the US Medicare 5% sample to the Observational Medical Outcome Partnership common data model (CDM).We completed and documented the process for the CDM conversion. The coordinating center and participating sites reviewed the documents and refined the conversions based on the comments. The time required to convert data to the CDM varied widely across sites and included conversion to standard terminology codes and refinements of the conversion based on reviews. We mapped 97.2%, 86.7%, 92.6%, and 80.1% of domestic drug codes from the USA, Taiwan, Hong Kong, and Korea to RxNorm, respectively. The mapping rate from Japanese domestic drug codes to RxNorm (70.7%) was lower than from other countries, and we mapped remaining unmapped drugs to Anatomical Therapeutic Chemical Classification System codes. Because the native databases used international procedure coding systems for which mapping tables have been established, we were able to map >90% of diagnosis and procedure codes to standard terminology codes.The CDM established the foundation and reinforced collaboration for multinational pharmacoepidemiologic studies in Asia. Mapping of terminology codes was the greatest challenge, because of differences in health systems, cultures, and coding systems.
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease.
M Alexander, AK Loomis, J Fairburn-Beech, J van der Lei, T Duarte-Salles, D Prieto-Alhambra, D Ansell, A Pasqua, F Lapi, P Rijnbeek, M Mosseveld, P Avillach, P Egger, S Kendrick, DM Waterworth, N Sattar and W Alazawi,
BMC medicine , 2018 13 08
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. It affects an estimated 20% of the general population, based on cohort studies of varying size and heterogeneous selection. However, the prevalence and incidence of recorded NAFLD diagnoses in unselected real-world health-care records is unknown. We harmonised health records from four major European territories and assessed age- and sex-specific point prevalence and incidence of NAFLD over the past decade.Data were extracted from The Health Improvement Network (UK), Health Search Database (Italy), Information System for Research in Primary Care (Spain) and Integrated Primary Care Information (Netherlands). Each database uses a different coding system. Prevalence and incidence estimates were pooled across databases by random-effects meta-analysis after a log-transformation.Data were available for 17,669,973 adults, of which 176,114 had a recorded diagnosis of NAFLD. Pooled prevalence trebled from 0.60% in 2007 (95% confidence interval: 0.41-0.79) to 1.85% (0.91-2.79) in 2014. Incidence doubled from 1.32 (0.83-1.82) to 2.35 (1.29-3.40) per 1000 person-years. The FIB-4 non-invasive estimate of liver fibrosis could be calculated in 40.6% of patients, of whom 29.6-35.7% had indeterminate or high-risk scores.In the largest primary-care record study of its kind to date, rates of recorded NAFLD are much lower than expected suggesting under-diagnosis and under-recording. Despite this, we have identified rising incidence and prevalence of the diagnosis. Improved recognition of NAFLD may identify people who will benefit from risk factor modification or emerging therapies to prevent progression to cardiometabolic and hepatic complications.
